杭州鼎乐新为生物

Dingle Xinwei is a China-based biotechnology company focused on the discovery and development of innovative small molecule therapeutics. The company leverages its proprietary drug discovery platform to target challenging biological pathways, particularly protein-protein interactions (PPIs) and other undruggable targets. Dingle Xinwei's pipeline primarily addresses unmet medical needs in oncology and immunology. Founded in 2021 and headquartered in Hangzhou, the company was established by Dr. Bo Li, a veteran of the pharmaceutical industry with significant experience at Eli Lilly. The firm has secured substantial financial backing from prominent venture capital firms, including Lilly Asia Ventures and Qiming Venture Partners. Dingle Xinwei aims to translate cutting-edge biological insights into first-in-class medicines for patients worldwide.